Topic

Bruce Liu is a partner at Simon-Kucher & Partners, leading its life sciences division in greater China.

Justinian Liu is a senior consultant for Simon-Kucher.

Duo Xu is a senior consultant for Simon-Kucher.

Shiying He is a senior consultant for Simon-Kucher.

Selene Peng is a senior consultant for Simon-Kucher.

Articles

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.    

China’s 2022 NRDL Readout

An ecosystem perspective is the first step.

Innovating the Go-to-Market Model in Asia 

Incyte Biosciences United Kingdom and Ireland Appoints Peter Williams As General Manager

AnaÃ¯s FrappÃ© is a Consultant at Simon-Kucher & Partners Life Sciences practice in New York.

Commercial Health Insurance may bring more opportunities for market access in China.

The Emergence of Commercial Health Insurances as an Access Route to the Chinese Market

Global go-to-market strategies in region require a revamped gameplan.

Cracking the Code to Commercial Promise in Asia 

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

China’s 2022 NRDL Outlook

The rare disease market in China can be summed up in three words: Exciting, challenging, and fast evolving. As such it’s quite a complicated space that requires a careful and strategic approach. In this article experts from Simon-Kucher discuss how best to navigate this landscape to reap the many opportunities available.

3 Steps to Navigate Rare Disease Market in China

Jimenez discusses bringing care to diverse and underserved communities.

Q&A With David Jimenez, President of Janssen Immunology

Industry leaders discuss new technologies, research, and investment strategies.

13th Annual PING Conference Highlights Future of UK Pharma Industry

Continent has shed its ‘emerging’ status on world biopharma stage.